Novonesis (Novozymes A/S) COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook. The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter. Ester Baiget, President & CEO, says: “We started the year with strong sales growth and earnings. This is a testament to our innovative solutions, resilient global business model, and our ability to continue to meet the increasing demand for biosolutions in an ever-changing world.” “Emerging markets were a key growth driver, and all our four sales areas grew by double digits. We’re pleased with our progress, and we maintain our full-year financial outlook.” “Overall, our Q1 performance underscores the value of our solutions in helping customers do more with less—enabling higher yields, improved throughput, enhanced performance, and greater benefits. And it shows that growth and planet stewardship can be two sides of the same coin.” During the first three months of the financial year, Novonesis launched six innovations including an advanced protease portfolio for swift and efficient stain removal. Divisional sales performance organic In the first three months of the financial year, Food & Health Biosolutions grew by 12%, while Planetary Health Biosolutions grew by 11%. In Food & Health Biosolutions, Food & Beverages grew by 11% with double-digit growth across most categories. In Human Health, organic sales growth was 13% driven by a strong development in Dietary Supplements. In Planetary Health Biosolutions, Household Care grew by 12%. The strong performance was driven by increased penetration and innovation. Agriculture, Energy & Tech grew by 10% driven by double-digit growth in Energy and Tech. Regional performance organic For the first quarter, emerging markets grew by 15% driven by all sales areas. Developed markets grew by 9%, driven by innovation. For Q1 2025, organic growth rates by geography were 14% in Europe, Middle East & Africa, 7% in North America, 9% in Asia Pacific, and 18% in Latin America. Outlook for 2025 The 2025 outlook is maintained at 5-8% organic sales growth (6-9% excluding the exit from certain countries) and an adjusted EBITDA margin between 37-38% despite current currency headwinds. The 2025 outlook is based on current levels of global trade tariffs. Our strong global setup, including flexible regional production capabilities, creates a diversified and resilient business. Additionally, we have confidence in passing on incremental cost driven by tariffs. As a result, we expect no or only marginal net impact from tariffs. Story Continues Financial calendar 2025 / 2026 August 21, 2025: H1 2025 financial results November 6, 2025: Q3 2025 financial results February 25, 2026: Full-year financial statement 2025 Media Relations Investor Relations Anne Sophie Scavenius Senior Media Relations Manager Phone: +45 30 77 19 67 [email protected] Tobias Cornelius Björklund Head of Investor Relations Phone: +45 30 77 86 82 [email protected] Attachments Q1 2025_Press Release_final 23079 NVS Q1 2025 Fact sheet v11 Q1 2025_Case_final View Comments
Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...